MIRM - FDA extends decision target date for Mirum drug Livmarli to March 13
2023-10-17 17:25:51 ET
More on Mirum Pharmaceuticals
- Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise
- Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Call Transcript
- Mirum Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals
- Historical earnings data for Mirum Pharmaceuticals
For further details see:
FDA extends decision target date for Mirum drug Livmarli to March 13